AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 221 min read$IBRX

ImmunityBio (IBRX): November ANKTIVA Trial Results Could Support Expanded FDA Filing?

ImmunityBio (IBRX) completed the database lock for its QUILT-2.005 trial, evaluating ANKTIVA plus BCG in BCG-naïve NMIBC patients. An FDA-requested interim analysis showed a statistically significant longer duration of complete response with the combination. Topline results are expected in November 2026, with a supplemental Biologics License Application planned for Q4 2026, according to the company.

Original reporting
rttnews.com
Published Oct 22, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IBRX
Bullish
high confidence
Mentioned
$IBRX
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$IBRXBullishLow
01

Why it matters

The interim analysis suggests a meaningful efficacy advantage, which could accelerate the upcoming sBLA filing and improve the company's valuation.

02

Market read

First public disclosure of positive interim trial data; may drive short‑term price appreciation ahead of the November topline results.

03

What to watch

Regulatory timing and potential competition from other NMIBC therapies could temper upside.

Relevance 8/10Novelty 8/10Timing: later this month (November 2026)

Background

ImmunityBio (IBRX) is a US‑listed biotech focused on cancer immunotherapies. The QUILT‑2.005 trial is a registrational study for ANKTIVA in BCG‑naïve non‑muscle invasive bladder cancer.

Company-level read

Ticker impact

$IBRXBullishHigh confidence
Context

ImmunityBio completed database lock and reported an FDA‑requested interim analysis showing significantly longer complete response duration for its ANKTIVA + BCG bladder cancer trial.

Expected impact

potential upside as market prices in the favorable interim results

Evidence & confidence

First disclosure of statistically significant trial data for a registrational study; biotech stocks typically react positively to such news.

Market effects

Sector

May lift sentiment for other bladder‑cancer immunotherapy peers.

Regional

Limited to US biotech investors.

Global

Modest, as trial pertains to a niche oncology indication.

Counterpoint

What could challenge this read

Investors may wait for full Phase 3 data before committing, as interim results can be misleading.

Key entities

  • company
    ImmunityBio, Inc.

    US‑listed biotech developing ANKTIVA for bladder cancer.

  • regulator
    FDA

    Requested the interim analysis for the trial.

Read at source← All news

StoryImmunityBio completes database lock for ANKTIVA bladder cancer trial, results due in November

Also covered by

1 outlet

Related articles

NOV 4
$IBRXMedAI 8/10

ImmunityBio, Inc.: ImmunityBio Announces First Patients in Europe Treated with ANKTIVA Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

ImmunityBio (NASDAQ: IBRX) announced the first European patients treated with ANKTIVA plus BCG for BCG-unresponsive bladder cancer. The treatment received conditional marketing authorization from the European Commission in February 2026. Accord Healthcare and Uniphar support commercialization and distribution across Europe.

finanznachrichten.de2 min
NOV 4
HighAI 8/10

ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

ImmunityBio has begun treating the first patients in Europe with ANKTIVA® plus BCG for BCG-unresponsive non-muscle invasive bladder cancer. The treatment received conditional marketing authorization from the European Commission in February 2026. Accord Healthcare and Uniphar are supporting commercialization and distribution efforts across Europe.

stocktitan.net2 min
OCT 26
$IBRXMedAI 9/10

Expanded Use for ImmunityBio Drug

ImmunityBio Inc. received FDA approval for expanded use of Anktiva to treat a more common form of bladder cancer, months ahead of schedule. The stock rose 4% on the news but has since fallen. Anktiva was initially approved in April 2024 for a rare form of bladder cancer. The FDA had rejected an earlier expanded use application but approved it in October 2024.

labusinessjournal.com3 min
OCT 21
$IBRXMedAI 8/10

IBRX Stock Rises: ImmunityBio Expects November Results For Anktiva Bladder Cancer Trial

ImmunityBio (IBRX) announced the completion of data collection for a 366-patient trial of ANKTIVA plus BCG in non-muscle invasive bladder cancer, with final results expected in November. The company reported a statistically significant interim analysis and plans to submit a supplemental Biologics License Application to the FDA in Q4 2026. IBRX shares rose 2% on the news.

stocktwits.com2 min
OCT 21
$IBRXMedAI 8/10

ImmunityBio completes database lock for bladder cancer trial

ImmunityBio (NASDAQ:IBRX) completed database lock for Cohort A of its QUILT-2.005 trial, evaluating ANKTIVA with BCG vs. BCG alone in BCG-naïve bladder cancer patients. Interim analysis showed longer complete response duration with the combination. Final results and FDA submission expected in Q4 2026. The trial enrolled 366 patients across 110 sites.

investing.com2 min